Timo Muhonen

1.7k total citations
56 papers, 1.1k citations indexed

About

Timo Muhonen is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Timo Muhonen has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 15 papers in Immunology and 12 papers in Molecular Biology. Recurrent topics in Timo Muhonen's work include Immunotherapy and Immune Responses (14 papers), Cutaneous Melanoma Detection and Management (12 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Timo Muhonen is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Cutaneous Melanoma Detection and Management (12 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Timo Muhonen collaborates with scholars based in Finland, Sweden and Bulgaria. Timo Muhonen's co-authors include Seppo Pyrhönen, Marjo Hahka‐Kemppinen, Ismo T. Jantunen, Vesa Kataja, Micaela Hernberg, Juha Pekka Turunen, Tatyana Vlaykova, T. Koskinen, Erkka Syvälahti and Hannu Naukkarinen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Timo Muhonen

52 papers receiving 1.1k citations

Peers

Countries citing papers authored by Timo Muhonen

Since Specialization

Citations

This map shows the geographic impact of Timo Muhonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timo Muhonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timo Muhonen more than expected).

Fields of papers citing papers by Timo Muhonen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timo Muhonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timo Muhonen. The network helps show where Timo Muhonen may publish in the future.

Co-authorship network of co-authors of Timo Muhonen

This figure shows the co-authorship network connecting the top 25 collaborators of Timo Muhonen. A scholar is included among the top collaborators of Timo Muhonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timo Muhonen. Timo Muhonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A two-level optimization approach to tree-level planning in continuous cover forest management 2025 ·Journal of Forestry Research ·Timo Pukkala, Yrjö Nuutinen, Timo Muhonen	0
2	607P Impact of primary tumour sidedness (PTS) on demographics, resectability, and outcome after metastasectomy +/- local ablative therapy (LAT), or systemic therapy in metastatic colorectal cancer patients (a RAXO substudy) 2023 ·Annals of Oncology ·Pia Österlund, Emerik Österlund, Päivi Halonen, (unknown), Arno Nordin, (unknown), Tapio Salminen, (unknown), Serge Aho, Annika Ålgars, Raija Ristamäki, Eetu Heervä, Raija Kallio, Annamarja Lamminmäki, (unknown), Timo Muhonen, Teijo Kuopio, Juha Kononen, Bengt Glimelius, Helena Isoniemi	1
3	Immunohistochemically Detectable Bcl-2 Expression in Metastatic Melanoma: Association with Survival and Treatment Response 2002 ·Oncology ·Tatyana Vlaykova, Lauri Talve, Marjo Hahka‐Kemppinen, Micaela Hernberg, Timo Muhonen, Yrjö Collan, Seppo Pyrhönen	28
4	Regimens With or Without Interferon-α as Treatment for Metastatic Melanoma and Renal Cell Carcinoma: An Overview of Randomized Trials 1999 ·Journal of Immunotherapy ·Micaela Hernberg, Seppo Pyrhönen, Timo Muhonen	37
5	Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression 1999 ·Melanoma Research ·Tatyana Vlaykova, P Laurila, Timo Muhonen, Marjo Hahka‐Kemppinen, Antti Jekunen, Kari Alitalo, Seppo Pyrhönen	56
6	The burden of genetic disease and attitudes towards gene testing in Alport syndrome 1999 ·Pediatric Nephrology ·(unknown), Olli Koskimies, Timo Muhonen, H Kääriäinen	12
7	Prognostic value of biomarkers in malignant melanoma 1998 ·Melanoma Research ·Micaela Hernberg, Juha Pekka Turunen, Kristina von Boguslawsky, Timo Muhonen, (unknown)	29
8	Urinary 5-Hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy 1998 ·European Journal of Cancer ·Rita Janes, Timo Muhonen, Ulla Karjalainen, Tom Wiklund	10
9	Breast cancer risk estimation in families with history of breast cancer 1997 ·British Journal of Cancer ·Timo Muhonen, Hannaleena Eerola, Paula Vehmanen, Heli Nevanlinna, (unknown), Carl Blomqvist, H Kääriäinen, Seppo Pyrhönen	2
10	Vascularity and prognosis of metastatic melanoma 1997 ·International Journal of Cancer ·Tatyana Vlaykova, Timo Muhonen, Marjo Hahka‐Kemppinen, Seppo Pyrhönen, Antti Jekunen	22
11	Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma Receiving Chemoimmunotherapy 1997 ·Journal of Immunotherapy ·Micaela Hernberg, Juha Pekka Turunen, Timo Muhonen, Seppo Pyrhönen	25
12	Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay???can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma? 1996 ·Melanoma Research ·Marjo Hahka‐Kemppinen, Timo Muhonen, Lauri Kangas, (unknown)	4
13	Effects of granisetron with doxorubicin or epirubicin on ECG intervals 1996 ·Cancer Chemotherapy and Pharmacology ·Ismo T. Jantunen, Vesa Kataja, Timo Muhonen, (unknown)	37
14	Radiation therapy of intracranial malignant melanoma 1996 ·Radiotherapy and Oncology ·(unknown), Timo Muhonen, Mikael Kajanti, Seppo Pyrhönen	28
15	Effect of overall treatment time on local control in radical radiotherapy for squamous cell carcinoma of esophagus 1995 ·International Journal of Radiation OncologyBiologyPhysics ·Mikael Kajanti, (unknown), Leena Kankaanranta, Timo Muhonen, Lars R. Holsti	33
16	Mouse Subrenal Capsule Assay Chemosensitivity and DNA Flow Cytometry Parameters of Human Melanoma Metastases 1994 ·Acta Oncologica ·Timo Muhonen, Seppo Pyrhönen, A. Laasonen, Veli-Matti Wasenius, Sirpa Asko‐Seljavaara, Kaarle Franssila, Lauri Kangas	2
17	Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients 1993 ·European Journal of Cancer ·A. G. Maiche, Timo Muhonen	19
18	Improving the prognostic value of DNA flow cytometry in metastatic melanoma by combinig ploidy and S-phase fraction 1992 ·Melanoma Research ·Timo Muhonen	1
19	DNA ploidy pattern and S-phase characteristics of metastatic melanoma 1991 ·Virchows Archiv B Cell Pathology Including Molecular Pathology ·Timo Muhonen, Seppo Pyrhönen, A. Laasonen, Sirpa Asko‐Seljavaara, Kaarle Franssila	4
20	Anti-melanoma antibodies bind preferentially to diploid metastases in immunoscintigraphy 1990 ·Nuclear Medicine Communications ·Seppo Pyrhönen, K. Liewendahl, Timo Muhonen, A. Laasonen, Sirpa Asko‐Seljavaara, (unknown), Kaarle Franssila, Pekka Virkkunen, A.-L. Brownell	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact